X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs NOVARTIS - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD NOVARTIS LUPIN LTD/
NOVARTIS
 
P/E (TTM) x 29.2 381.9 7.6% View Chart
P/BV x 2.8 33.6 8.3% View Chart
Dividend Yield % 0.6 1.4 43.8%  

Financials

 LUPIN LTD   NOVARTIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
NOVARTIS
Mar-18
LUPIN LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,465758 193.3%   
Low Rs727579 125.6%   
Sales per share (Unadj.) Rs349.6228.4 153.1%  
Earnings per share (Unadj.) Rs5.631.7 17.5%  
Cash flow per share (Unadj.) Rs29.632.8 90.3%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.51.5 30.5%  
Book value per share (Unadj.) Rs300.3297.1 101.1%  
Shares outstanding (eoy) m452.0824.69 1,831.0%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.12.9 107.1%   
Avg P/E ratio x197.221.1 936.3%  
P/CF ratio (eoy) x37.120.4 181.6%  
Price / Book Value ratio x3.62.2 162.2%  
Dividend payout %90.031.5 285.5%   
Avg Mkt Cap Rs m495,50216,505 3,002.1%   
No. of employees `00017.00.7 2,551.2%   
Total wages/salary Rs m28,6471,445 1,982.1%   
Avg. sales/employee Rs Th9,273.68,441.3 109.9%   
Avg. wages/employee Rs Th1,681.02,163.6 77.7%   
Avg. net profit/employee Rs Th147.41,173.1 12.6%   
INCOME DATA
Net Sales Rs m158,0425,639 2,802.8%  
Other income Rs m1,5041,718 87.5%   
Total revenues Rs m159,5457,357 2,168.6%   
Gross profit Rs m31,475-63 -50,360.2%  
Depreciation Rs m10,85925 42,919.8%   
Interest Rs m2,04455 3,695.3%   
Profit before tax Rs m20,0761,575 1,274.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,885792 364.4%   
Profit after tax Rs m2,513784 320.6%  
Gross profit margin %19.9-1.1 -1,796.8%  
Effective tax rate %14.450.3 28.6%   
Net profit margin %1.613.9 11.4%  
BALANCE SHEET DATA
Current assets Rs m122,0959,522 1,282.3%   
Current liabilities Rs m50,9563,296 1,546.0%   
Net working cap to sales %45.0110.4 40.8%  
Current ratio x2.42.9 82.9%  
Inventory Days Days8537 231.0%  
Debtors Days Days12028 421.9%  
Net fixed assets Rs m129,87646 282,339.8%   
Share capital Rs m904123 732.7%   
"Free" reserves Rs m134,8667,213 1,869.8%   
Net worth Rs m135,7717,336 1,850.6%   
Long term debt Rs m64,2450-   
Total assets Rs m263,05411,105 2,368.7%  
Interest coverage x10.829.5 36.7%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.5 118.3%   
Return on assets %1.77.6 22.9%  
Return on equity %1.910.7 17.3%  
Return on capital %3.722.2 16.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14161 87,691.9%   
Fx outflow Rs m19,3353,630 532.6%   
Net fx Rs m33,807-3,570 -947.1%   
CASH FLOW
From Operations Rs m17,5121,610 1,087.8%  
From Investments Rs m-14,073687 -2,048.4%  
From Financial Activity Rs m-14,921-2,677 557.5%  
Net Cashflow Rs m-11,482-380 3,024.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 31.9 1.6 1,993.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.5 47.0%  
Shareholders   98,259 41,647 235.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare LUPIN LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Dec 7, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS